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Clinical PerspectiveWhat Is New?In blacks, ≈30% of men and women were estimated to develop peripheral artery disease (PAD) during their lifetime, whereas in whites and Hispanics the corresponding estimate is ≈20%.From another perspective, blacks reached a 10% lifetime risk for PAD ≈10 years earlier than whites and Hispanics.Current and former smoking, diabetes mellitus, and a history of other cardiovascular disease were particularly potent predictors of developing PAD, contributing to ≈5‐fold gradient of residual lifetime risk and ≈10‐fold gradient of the probability of prevalent PAD at a given age, sex, and race/ethnicity.What Are the Clinical Implications?Although major guidelines for PAD did not specify black race as a risk factor of PAD, our results suggest the importance for healthcare providers to keep in mind this disproportional risk of PAD in blacks.Risk calculators for the lifetime risk of PAD as well as prevalent PAD have been developed from this study, which may contribute to comprehensive cardiovascular risk assessment and inform targeted PAD screening.

 {#jah34369-sec-0008}

Lifetime risk is useful for communicating long‐term risk and estimating the future burden of disease in populations.[1](#jah34369-bib-0001){ref-type="ref"}, [2](#jah34369-bib-0002){ref-type="ref"}, [3](#jah34369-bib-0003){ref-type="ref"}, [4](#jah34369-bib-0004){ref-type="ref"}, [5](#jah34369-bib-0005){ref-type="ref"} Lifetime risk estimation of coronary heart disease and stroke is recommended in the American Heart Association and the American College of Cardiology guidelines for guiding preventive therapies.[6](#jah34369-bib-0006){ref-type="ref"}, [7](#jah34369-bib-0007){ref-type="ref"} However, to our knowledge, there are no available estimates of lifetime risk of lower‐extremity peripheral artery disease (PAD), despite its impact on prognosis,[8](#jah34369-bib-0008){ref-type="ref"} leg amputation,[9](#jah34369-bib-0009){ref-type="ref"} and physical function.[10](#jah34369-bib-0010){ref-type="ref"} Here, using data from 6 US community‐based cohorts with over 35 000 unique participants, we estimated lifetime risk of PAD by sex and among 3 racial/ethnic groups (whites, blacks, and Hispanics). Subsequently, we extended the lifetime risk estimations by age and other traditional atherosclerotic risk factors, which would complement lifetime risk prediction of coronary disease and stroke in the American Heart Association/American College of Cardiology guidelines[6](#jah34369-bib-0006){ref-type="ref"}, [7](#jah34369-bib-0007){ref-type="ref"} and facilitate personalized and comprehensive cardiovascular risk discussion between healthcare providers and patients.[6](#jah34369-bib-0006){ref-type="ref"}, [11](#jah34369-bib-0011){ref-type="ref"}

Methods {#jah34369-sec-0009}
=======

This study was approved by the institutional review board for use of deidentified data at the Johns Hopkins Bloomberg School of Public Health (Baltimore, MD), and the need for informed consent was waived. Each participating cohort has its own policy for data sharing, but some of their data are publicly available (the National Health and Nutrition Examination Survey \[NHANES\] through the Centers for Disease Control and Prevention\'s website[12](#jah34369-bib-0012){ref-type="ref"} and other cohorts through BioLINCC[13](#jah34369-bib-0013){ref-type="ref"}).

Lifetime Risk Estimation {#jah34369-sec-0010}
------------------------

There are 2 main approaches to estimate lifetime risk in the literature: (1) estimating long‐term cumulative incidence from a survival analysis of individuals[14](#jah34369-bib-0014){ref-type="ref"}, [15](#jah34369-bib-0015){ref-type="ref"}, [16](#jah34369-bib-0016){ref-type="ref"} and (2) estimating lifetime risk using Monte Carlo simulations with state transition probabilities based on a Markov chain model.[1](#jah34369-bib-0001){ref-type="ref"}, [2](#jah34369-bib-0002){ref-type="ref"} The former approach may sound more intuitive than the latter, but because there are few cohort studies with lifelong follow‐up, the former approach often needs to stack cumulative incidences from different risk sets with different age categories. For example, to obtain lifetime risk from the age of 40 in a cohort with an age range of 40 to 80 years and follow‐up of 20 years, cumulative incidence before and after the age of 60 years should rely on younger and older study populations, respectively, which potentially induces some biases (eg, birth cohort effects). Also, the former approach is likely to be particularly suboptimal for clinical conditions without evident signs or symptoms, as incidences may not be appropriately captured in any cohort studies. This issue is especially relevant to PAD because the vast majority of disease is asymptomatic or accompanied by atypical leg symptoms.[17](#jah34369-bib-0017){ref-type="ref"} Also, very few cohort studies have regularly repeated measurement of ankle‐brachial index (ABI) in a relatively short elapsed time to capture asymptomatic cases to minimize the number of losses to follow‐up or deaths between repeated ABI measurements. Thus, we estimated the lifetime risk of PAD using the Monte Carlo simulations approach.[2](#jah34369-bib-0002){ref-type="ref"}

A Markov chain model was constructed to simulate progression of an initially PAD free individual of a given baseline age, sex, and race/ethnicity through the mutually exclusive states of no PAD, PAD, and death, with PAD and death treated as "absorbing states" (once entered unable to leave) (Data [S1](#jah34369-sup-0001){ref-type="supplementary-material"}). State transition probabilities of interest were (1) the probability of developing PAD (I~PAD~) and (2) the probability of dying prior to the development of PAD (Q~noPAD~). Details for the calculations of each state transition probability are provided subsequently in the section "State Transition Probabilities and Data Sources" below as well as in Data [S1](#jah34369-sup-0001){ref-type="supplementary-material"}. Using these state transition probabilities, Monte Carlo simulations were performed 100 000 times from the age of 0 through 80 years with a cycle length of 1 year, which is equivalent to a simulated cohort of 100 000 individuals of a specified baseline age, sex, and race with a lifetime horizon capped at 80 years. All analyses were performed by Stata 14 (StataCorp LP, College Station, TX).

State Transition Probabilities and Data Sources {#jah34369-sec-0011}
-----------------------------------------------

Q~noPAD~ (1‐year probability of dying among people free of PAD of a given age, sex, and race) was calculated from age‐, sex‐, and race/ethnicity‐specific estimates of annual mortality in the overall population (ie, populations with and without PAD), the prevalence of PAD, and hazard ratios for mortality associated with PAD. This approach is based on the fact that annual overall mortality can be viewed as a weighted average of the 1‐year probability of dying among people with PAD and that of those without PAD.[2](#jah34369-bib-0002){ref-type="ref"} Annual probabilities of death for the US population by each year of age, sex, and race/ethnicity (whites, blacks, and Hispanics) were based on the National Vital Statistics Report.[18](#jah34369-bib-0018){ref-type="ref"} The prevalence of PAD according to ABI \<0.90[19](#jah34369-bib-0019){ref-type="ref"}, [20](#jah34369-bib-0020){ref-type="ref"} was based on data from a total of 6 US community‐based cohorts (5 cohorts with ABI data included in the Cardiovascular Lifetime Risk Pooling Project,[21](#jah34369-bib-0021){ref-type="ref"} namely, the ARIC \[Atherosclerosis Risk in Communities\] study,[22](#jah34369-bib-0022){ref-type="ref"} the CHS \[Cardiovascular Health Study\],[23](#jah34369-bib-0023){ref-type="ref"} the FHS \[Framingham Heart Study\],[24](#jah34369-bib-0024){ref-type="ref"} the FOF \[Framingham Offspring study\], and the MESA \[Multi‐Ethnic Study of Atherosclerosis\],[25](#jah34369-bib-0025){ref-type="ref"} as well as NHANES 1999--2004).[26](#jah34369-bib-0026){ref-type="ref"} Data collection in each study was conducted according to a standardized protocol as previously reported,[22](#jah34369-bib-0022){ref-type="ref"}, [23](#jah34369-bib-0023){ref-type="ref"}, [24](#jah34369-bib-0024){ref-type="ref"}, [25](#jah34369-bib-0025){ref-type="ref"} and details of how ABI was measured in each cohort are summarized in Data [S2](#jah34369-sup-0001){ref-type="supplementary-material"}. The relative risk of mortality for PAD versus no PAD was also obtained from pooled data from these 6 US community‐based cohorts.

I~PAD~ (the probability of developing PAD at a given age) was estimated from age‐, sex‐, and race/ethnicity‐specific estimates of annual mortality in the overall population, Q~noPAD~ (detailed above), age‐, sex‐, and race/ethnicity‐specific prevalence of no PAD (ie, 1‐ the prevalence of PAD). This approach is based on the fact that the prevalence of no PAD at age x+1 is determined by 3 elements, the prevalence of no PAD at age x (denominator) and 2 types of exits from no PAD, annual incidence of PAD during age x or mortality among no PAD during age x (ie, Q~noPAD~). Data sources for these parameters were the same as those noted above for Q~noPAD~. More details about state transition probabilities are provided in Data [S1](#jah34369-sup-0001){ref-type="supplementary-material"}.

Estimating the Prevalence of PAD {#jah34369-sec-0012}
--------------------------------

Logistic regression models with age, sex, and race/ethnicity as independent variables were used to estimate the prevalence of PAD. To improve the precision of age‐, sex‐, and race/ethnicity‐specific estimates of PAD prevalence, we used the pooled data of the 6 US cohort studies (indicators of 6 cohorts were included in logistic models).[2](#jah34369-bib-0002){ref-type="ref"} Because NHANES is most representative of US populations among the 6 cohorts (although data were somewhat sparse in some age and race/ethnic groups), we combined the odds of PAD in a base case of 70‐year‐old white men in NHANES and odds ratios for age, sex, and race/ethnicity from the pooled data to estimate the prevalence of PAD for each year of age among sex and race/ethnicity groups (white men and women, black men and women, and Hispanic men and women). In this step, we used sample weights in NHANES. We also incorporated significant product terms between age, race/ethnicity, and sex.

Estimating Relative Risk of Mortality for PAD Versus No PAD {#jah34369-sec-0013}
-----------------------------------------------------------

The relative risk of mortality for PAD (ABI \<0.90) versus no PAD (ABI ≥0.90) was obtained from pooled data from the 6 US community‐based cohorts using stratified Cox proportional hazards models. Cox models were adjusted for sex and race/ethnicity and incorporated interaction terms between PAD and age with splines (knots at age 65 years). Again, indicator variables for 6 cohorts were included in regression models.

Residual Lifetime Risk by Age and Traditional Atherosclerotic Risk Factors {#jah34369-sec-0014}
--------------------------------------------------------------------------

Lifetime risk estimates from a given age (ie, residual lifetime risk) can be viewed as a weighted average of residual lifetime risk of subgroups determined by combinations of the presence and absence (or higher and lower values if continuous factors) of traditional risk factors at that given age. Using sample weights and actual values of traditional atherosclerotic risk factors in NHANES, as well as odds ratio of PAD for traditional atherosclerotic risk factors from the pooled data of 6 studies, we estimated residual lifetime risk by combinations of age and traditional atherosclerotic risk factors. More details can be found in Data [S3](#jah34369-sup-0001){ref-type="supplementary-material"}.

Logistic regression models to estimate odds ratios of PAD in the pooled data of the 6 US cohort studies included diabetes mellitus, smoking (both current and former), systolic blood pressure, high‐density lipoprotein cholesterol, total cholesterol, and a history of coronary heart disease or stroke as well as age, sex, race/ethnicity, and study indicators.

Results {#jah34369-sec-0015}
=======

Study Characteristics {#jah34369-sec-0016}
---------------------

A total of 38 154 participants were included from the 6 cohorts, of whom 2517 participants (6.6%) had PAD based on an ABI \<0.90. Whites and blacks were included in 4 cohorts: ARIC, CHS, MESA, and NHANES (Table [1](#jah34369-tbl-0001){ref-type="table"}). Hispanics were represented in 2 cohorts, MESA and NHANES. The mean age ranged from 55 to 80 years across the cohorts. Compared with cohorts with a lower average age, cohorts with an older average age tended to have a less favorable risk factor profile (eg, higher blood pressure and prevalence of diabetes mellitus). The prevalence of current smokers was highest in ARIC (26%) and lowest in FHS (6.7%). The prevalence of PAD varied from 3.8% in MESA to 21% in FHS. Generally consistent across cohorts, a history of coronary heart disease and stroke as well as most traditional atherosclerotic risk factors (ie, ever smokers, low high‐density lipoprotein cholesterol, and diabetes mellitus) were more prevalent in men than in women (Table [S1](#jah34369-sup-0001){ref-type="supplementary-material"}).

###### 

Study Characteristics

                                          Study                                                                  
  --------------------------------------- -------------- ------------- ------------- ------------- ------------- -------------
  Total of death, N (%)                   4272 (30%)     4608 (81%)    430 (72%)     380 (12%)     1144 (17%)    1516 (21%)
  Follow‐up time (y), mean (SD)           18.4 (5.2)     13.1 (6.5)    9.1 (3.9)     10.3 (2.1)    12.4 (2.5)    9.0 (2.6)
  Age (y), mean (SD)                      55 (5.9)       72 (5.5)      80 (3.9)      58 (9.6)      62 (10)       60 (13)
  Female sex, N (%)                       7757 (54%)     3234 (57%)    376 (63%)     1870 (53%)    3573 (53%)    3581 (48%)
  Race/Ethnicity, N (%)                                                                                          
  White                                   10 719 (75%)   4790 (85%)    597 (100%)    3520 (100%)   2614 (39%)    4092 (56%)
  Black                                   3555 (25%)     837 (15%)     ...           ...           1868 (28%)    1361 (19%)
  Hispanic                                ...            35 (0.62%)    ...           ...           2290 (34%)    1876 (26%)
  Smoking status, N (%)                                                                                          
  Never                                   5863 (41%)     2615 (47%)    557 (93%)     2977 (85%)    3403 (50%)    3063 (42%)
  Former                                  4699 (33%)     2369 (42%)    ...           ...           2489 (37%)    3292 (45%)
  Current                                 3712 (26%)     678 (12%)     40 (6.7%)     543 (15%)     880 (13%)     967 (13%)
  SBP (mm Hg), mean (SD)                  121 (19)       136 (22)      143 (21)      128 (18)      126 (21)      132 (21)
  Total cholesterol (mmol/L), mean (SD)   5.6 (1.1)      5.5 (1.0)     5.3 (1.0)     5.3 (1.0)     5.0 (0.9)     5.4 (1.1)
  HDL cholesterol (mmol/L), mean (SD)     1.3 (0.4)      1.4 (0.4)     1.3 (0.4)     1.3 (0.4)     1.3 (0.4)     1.4 (0.4)
  Diabetes mellitus, N (%)                1579 (11%)     837 (15%)     130 (22%)     336 (9.6%)    848 (13%)     1200 (16%)
  History of CHD or stroke, N (%)         1796 (13%)     893 (16%)     136 (23%)     221 (6.3%)    5 (0.07%)     914 (13%)
  ABI, mean (SD)                          1.13 (0.14)    1.06 (0.18)   1.01 (0.21)   1.11 (0.12)   1.11 (0.12)   1.09 (0.16)
  PAD (ABI \<0.90), N (%)                 634 (4.4%)     759 (13%)     124 (21%)     112 (3.2%)    255 (3.8%)    633 (8.6%)

ABI indicates ankle‐brachial index; ARIC, Atherosclerosis Risk in Communities study; CHD, coronary heart disease; CHS, Cardiovascular Health Study; FHS, Framingham Heart Study; FOF, Framingham Offspring study; HDL, high‐density lipoprotein; MESA, Multi‐Ethnic Study of Atherosclerosis; NHANES, National Health and Nutrition Examination Survey; PAD, peripheral artery disease; SBP, systolic blood pressure.
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Estimates of PAD Prevalence and Mortality Risk Associated With PAD {#jah34369-sec-0017}
------------------------------------------------------------------

Pooled results from logistic regression models confirmed age as a strong predictor of prevalent PAD, with an odds ratio of 1.56 (95% CI, 1.50--1.61) per 5‐year increment (Table [S2](#jah34369-sup-0001){ref-type="supplementary-material"}). At 65 years of age, women had slightly higher odds of having ABI \<0.90 than men (odds ratio, 1.24 \[95% CI, 1.12--1.38\]), and this sex‐difference was slightly but significantly attenuated with older age (as represented by odds ratio of 0.90 \[per 5‐year increment\] for the product term of female and age). Compared with whites, blacks had \>2‐fold higher odds of having PAD (eg, 2.16 \[95% CI, 1.86--2.52\] for black men versus white men), without any difference by age. Hispanics had significantly lower odds of PAD than whites, especially in middle age (eg, 0.76 \[95% CI, 0.62--0.93\] for men at 65 years of age versus white men), but this difference was attenuated at older ages (1.16 \[95% CI, 1.06--1.27\] for the product term of age and Hispanic ethnicity). Estimates of PAD prevalence were higher in blacks than the other 2 racial/ethnic groups in either sex at any age (Figure [S1](#jah34369-sup-0001){ref-type="supplementary-material"}).

Pooled Cox models demonstrated a sex‐ and race/ethnicity‐adjusted hazard ratio of 2.43 (95% CI, 2.18--2.72 at age of 65 years) for total mortality comparing PAD (ABI \<0.90) versus no PAD (ABI ≥0.90) (Table [S3](#jah34369-sup-0001){ref-type="supplementary-material"}). The strength of association was slightly attenuated in older age (13% \[95% CI, 8--17%\] smaller hazard ratio per 5 year older age above 65 years) (Table [S3](#jah34369-sup-0001){ref-type="supplementary-material"}).

Lifetime Risk Estimates by Sex and Race/Ethnicity {#jah34369-sec-0018}
-------------------------------------------------

Using estimates of PAD prevalence and relative risk of mortality for PAD in the prior section as well as national mortality data, we estimated Q~noPAD~ (1‐year probability of dying among people of a given age, sex, and race/ethnicity and free of PAD) and I~PAD~ (the probability of developing PAD at a given age) at each age from birth to 80 years in each sex and racial/ethnic group (Table [S4](#jah34369-sup-0001){ref-type="supplementary-material"}). On the basis of these estimates, the lifetime risk estimate was highest in black men, at 30.0%, followed by 27.6% in black women ([Figure](#jah34369-fig-0001){ref-type="fig"}). The lifetime risk estimate was similar in white men and women, with a lifetime risk of ≈19%, and Hispanic men and women, with a lifetime risk of ≈22%.

![Lifetime cumulative incidence of PAD by race and sex. ABI indicates ankle‐brachial index; PAD, peripheral artery disease.](JAH3-8-e012177-g001){#jah34369-fig-0001}

Residual Lifetime Risk of PAD by Traditional Risk Factors {#jah34369-sec-0019}
---------------------------------------------------------

Even after accounting for other traditional risk factors, age remained a strong predictor of PAD with an adjusted hazard ratio of 1.47 (95% CI, 1.43--1.52) (Table [2](#jah34369-tbl-0002){ref-type="table"}). Again, women had slightly higher odds of having an ABI \<0.90 than men. Compared with whites, blacks had higher odds and Hispanics had lower odds of having PAD. All of the other traditional risk factors---diabetes mellitus, smoking (both current and former), systolic blood pressure, high‐density lipoprotein cholesterol, total cholesterol, and a history of other cardiovascular disease---demonstrated significant associations with prevalent PAD.

###### 

Adjusted Pooled OR of Having ABI \<0.90

  Variables                               Pooled OR (95% CI)
  --------------------------------------- --------------------
  Age, 5 y                                1.47 (1.43, 1.52)
  Female                                  1.31 (1.19, 1.44)
  Black                                   1.65 (1.48, 1.84)
  Hispanic                                0.78 (0.64, 0.94)
  Diabetes mellitus                       1.54 (1.38, 1.71)
  Former smoker                           1.50 (1.34, 1.67)
  Current smoker                          3.09 (2.74, 3.49)
  SBP, 20 mm Hg                           1.27 (1.22, 1.32)
  HDL cholesterol, 1 mmol/L               0.68 (0.60, 0.76)
  Total cholesterol, 1 mmol/L             1.14 (1.09, 1.19)
  History of coronary disease or stroke   2.01 (1.81, 2.24)

All variables were modeled simultaneously. ABI indicates ankle‐brachial index; HDL, high‐density lipoprotein; OR, odds ratio; SBP, systolic blood pressure.

John Wiley & Sons, Ltd

On the basis of these estimates, we developed a calculator for residual lifetime risk as well as probability of prevalent PAD (<http://ckdpcrisk.org/padrisk> and every step is summarized in Data [S4](#jah34369-sup-0001){ref-type="supplementary-material"}). According to this calculator, we observed a gradient of residual lifetime risk of PAD in the same race/ethnicity exceeding 3.5‐ to 5‐fold according to traditional risk factors. For example, the residual risk varied from 19.9% to 70.4% in black men aged 45 years according to combinations of smoking, diabetes mellitus, and history of cardiovascular disease (Table [3](#jah34369-tbl-0003){ref-type="table"}). For an individual at age 65 years, because of the shorter duration to 80 years of age, the residual cumulative incidence was consistently lower than the scenario for an individual at age 45 years, at a given combination of traditional risk factors. Still, there was a 4‐ to 5.5‐fold gradient of residual lifetime risk of PAD according to smoking, diabetes mellitus, and a history of coronary disease or stroke within the same sex and race/ethnicity even in this scenario of a 65‐year‐old individual.

###### 

Projected Residual Cumulative Incidence (%) of PAD in the United States Across Different Scenarios of Demographic and Clinical Factors

  Demographic and clinical factors   Male   Female
  ---------------------------------- ------ --------
  *Age 45 y*                                
  Whites                                    
  Nonsmoker                                 
  No history of CHD or stroke               
  No diabetes mellitus               11.3   13.4
  Diabetes mellitus                  16.4   19.2
  History of CHD or stroke                  
  No diabetes mellitus               20.5   23.7
  Diabetes mellitus                  28.4   32.4
  Current smoker                            
  No history of CHD or stroke               
  No diabetes mellitus               28.4   32.4
  Diabetes mellitus                  37.8   42.4
  History of CHD or stroke                  
  No diabetes mellitus               44.4   49.1
  Diabetes mellitus                  55.0   59.7
  Blacks                                    
  Nonsmoker                                 
  No history of CHD or stroke               
  No diabetes mellitus               19.9   17.7
  Diabetes mellitus                  27.6   24.8
  History of CHD or stroke                  
  No diabetes mellitus               33.3   30.2
  Diabetes mellitus                  43.4   39.9
  Current smoker                            
  No history of CHD or stroke               
  No diabetes mellitus               43.4   39.9
  Diabetes mellitus                  54.1   50.5
  History of CHD or stroke                  
  No diabetes mellitus               60.7   57.2
  Diabetes mellitus                  70.4   67.2
  *Age 65 y*                                
  Whites                                    
  Nonsmoker                                 
  No history of CHD or stroke               
  No diabetes mellitus               8.0    8.2
  Diabetes mellitus                  11.7   12.1
  History of CHD or stroke                  
  No diabetes mellitus               14.8   15.3
  Diabetes mellitus                  21.1   21.7
  Current smoker                            
  No history of CHD or stroke               
  No diabetes mellitus               21.1   21.7
  Diabetes mellitus                  29.1   29.8
  History of CHD or stroke                  
  No diabetes mellitus               35.0   35.8
  Diabetes mellitus                  45.3   46.1
  Blacks                                    
  Nonsmoker                                 
  No history of CHD or stroke               
  No diabetes mellitus               16.8   12.9
  Diabetes mellitus                  23.7   18.6
  History of CHD or stroke                  
  No diabetes mellitus               29.0   23.0
  Diabetes mellitus                  38.5   31.5
  Current smoker                            
  No history of CHD or stroke               
  No diabetes mellitus               38.5   31.5
  Diabetes mellitus                  49.0   41.4
  History of CHD or stroke                  
  No diabetes mellitus               55.8   48.1
  Diabetes mellitus                  66.0   58.7

Scenarios are all for a systolic blood pressure of 130 mmHg, high‐density lipoprotein cholesterol of 50 mg/dL, and total cholesterol of 200 mg/dL. CHD indicates coronary heart disease; PAD, peripheral artery disease.
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Predicting Prevalent PAD by Traditional Risk Factors {#jah34369-sec-0020}
----------------------------------------------------

Using odds ratios of PAD according to traditional risk factors in Table [2](#jah34369-tbl-0002){ref-type="table"} as well as the prevalence of PAD in the aforementioned base case in NHANES, we developed a calculator to predict the probability of having PAD as well. To cross‐validate this approach, we split NHANES into 3 data sets (1999--2000, 2001--2002, and 2003--2004), developed a prediction model using 2 data sets, and compared predicted versus observed using the remaining data set. We indeed confirmed decent calibration (particularly in higher risk groups with all *P*\>0.1 in the top 5 deciles for 3 cross‐validation scenarios) and discrimination (cross‐validated c‐statistic=0.75) (Figure [S2](#jah34369-sup-0001){ref-type="supplementary-material"}). To maximize available data for best predicting the probability of having PAD, the final model used the whole NHANES data, which demonstrated good calibration (χ^2^ of 10.2 with *P*=0.35) and discrimination (c‐statistic=0.77) (Figure [S3](#jah34369-sup-0001){ref-type="supplementary-material"}). The variation of predicted probability of having PAD in several scenarios is shown in Table [4](#jah34369-tbl-0004){ref-type="table"}. The probability of having PAD within the same age, sex, and race/ethnicity varied by 6‐ to 10‐fold by smoking status, diabetes mellitus, and a history of coronary disease or stroke (eg, predicted probability from 1.2% to 10.5% in 45‐year‐old black men).

###### 

Estimated Probability of Prevalent PAD (%) in the United States Across Different Scenarios of Demographic and Clinical Factors

  Demographic and clinical factors   Male   Female
  ---------------------------------- ------ --------
  *Age 45 y*                                
  Whites                                    
  Nonsmoker                                 
  No history of CHD or stroke               
  No diabetes mellitus               0.6    1.4
  Diabetes mellitus                  0.9    2.1
  History of CHD or stroke                  
  No diabetes mellitus               1.2    2.7
  Diabetes mellitus                  1.8    4.1
  Current smoker                            
  No history of CHD or stroke               
  No diabetes mellitus               1.8    4.1
  Diabetes mellitus                  2.8    6.2
  History of CHD or stroke                  
  No diabetes mellitus               3.6    8.0
  Diabetes mellitus                  5.5    11.8
  Blacks                                    
  Nonsmoker                                 
  No history of CHD or stroke               
  No diabetes mellitus               1.2    1.8
  Diabetes mellitus                  1.8    2.8
  History of CHD or stroke                  
  No diabetes mellitus               2.4    3.6
  Diabetes mellitus                  3.6    5.5
  Current smoker                            
  No history of CHD or stroke               
  No diabetes mellitus               3.6    5.5
  Diabetes mellitus                  5.5    8.2
  History of CHD or stroke                  
  No diabetes mellitus               7.1    10.4
  Diabetes mellitus                  10.5   15.2
  *Age 65 y*                                
  Whites                                    
  Nonsmoker                                 
  No history of CHD or stroke               
  No diabetes mellitus               2.7    4.3
  Diabetes mellitus                  4.1    6.4
  History of CHD or stroke                  
  No diabetes mellitus               5.3    8.2
  Diabetes mellitus                  7.9    12.1
  Current smoker                            
  No history of CHD or stroke               
  No diabetes mellitus               7.9    12.1
  Diabetes mellitus                  11.7   17.5
  History of CHD or stroke                  
  No diabetes mellitus               14.8   21.7
  Diabetes mellitus                  21.1   29.9
  Blacks                                    
  Nonsmoker                                 
  No history of CHD or stroke               
  No diabetes mellitus               6.6    6.9
  Diabetes mellitus                  9.8    10.3
  History of CHD or stroke                  
  No diabetes mellitus               12.4   13.1
  Diabetes mellitus                  17.9   18.8
  Current smoker                            
  No history of CHD or stroke               
  No diabetes mellitus               17.9   18.8
  Diabetes mellitus                  25.1   26.2
  History of CHD or stroke                  
  No diabetes mellitus               30.5   31.7
  Diabetes mellitus                  40.3   41.7

Scenarios are all for a systolic blood pressure of 130 mmHg, high‐density lipoprotein cholesterol of 50 mg/dL, and total cholesterol of 200 mg/dL. CHD indicates coronary heart disease; PAD, peripheral artery disease.

John Wiley & Sons, Ltd

Discussion {#jah34369-sec-0021}
==========

Using data from 6 US community‐based cohorts, this study reported lifetime risk estimation of PAD. In blacks, ≈30% of men and women were estimated to develop PAD during their lifetime, whereas in whites and Hispanics the corresponding estimate is ≈20%. From another perspective, blacks reached a 10% lifetime risk for PAD 8 to 11 years earlier than whites and Hispanics. Women had a similar lifetime risk of PAD as men in all racial/ethnic groups. As anticipated, smoking (both current and former), diabetes mellitus, and a history of other cardiovascular disease were particularly potent predictors of developing PAD, contributing to an ≈5‐fold gradient of residual lifetime risk and ≈10‐fold gradient of the probability of prevalent PAD at a given age, sex, and race/ethnicity.

The higher lifetime risk of PAD in blacks compared with whites and Hispanics in our study is consistent with prevalence data shown in previous studies.[27](#jah34369-bib-0027){ref-type="ref"}, [28](#jah34369-bib-0028){ref-type="ref"} It is possible that this is partially explained by poor risk factor profiles in blacks compared with the other 2 groups, but this pattern remained consistent even after accounting for key traditional atherosclerotic risk factors in the present study (Table [2](#jah34369-tbl-0002){ref-type="table"}) as well as in previous studies.[29](#jah34369-bib-0029){ref-type="ref"} In this context, a recent study has demonstrated that socioeconomic factors such as education, household income, and neighborhood deprivation are associated with PAD risk beyond traditional risk factors.[30](#jah34369-bib-0030){ref-type="ref"} Nonetheless, although major guidelines for PAD did not specify black race as a risk factor for PAD,[19](#jah34369-bib-0019){ref-type="ref"} our results suggest the importance for healthcare providers to keep in mind this disproportional risk of PAD in blacks.

We observed a slightly higher prevalence of PAD in women than in men, particularly below 65 years of age (and similar lifetime risk of PAD between women and men). This may seem counterintuitive in light of epidemiology of other atherosclerotic diseases such as coronary disease, but several previous community‐based studies report the same pattern for PAD prevalence.[27](#jah34369-bib-0027){ref-type="ref"}, [31](#jah34369-bib-0031){ref-type="ref"}, [32](#jah34369-bib-0032){ref-type="ref"} Some reports suggest that this may be partially explained by shorter height in women than in men, potentially influencing ankle blood pressure.[33](#jah34369-bib-0033){ref-type="ref"}, [34](#jah34369-bib-0034){ref-type="ref"} Importantly, this cannot be simply interpreted as misclassification, as ABI \<0.90 conferred a 2‐fold higher risk of mortality as compared with the reference category of 1.1 to 1.2 in both men and women.[8](#jah34369-bib-0008){ref-type="ref"} Nonetheless, as the American Heart Association called for action,[35](#jah34369-bib-0035){ref-type="ref"} further studies are need for PAD in women, including investigations of its similar burden between men and women. In this context, it will be important to evaluate lifetime risk specifically for severe types of PAD requiring leg revascularization or amputation in both sexes.

There seem to be a few ways to use the risk calculators from this study. For example, our lifetime risk calculator can be complementary to the American Heart Association/American College of Cardiology lifetime risk calculator for coronary disease and stroke[7](#jah34369-bib-0007){ref-type="ref"} and may contribute to comprehensive cardiovascular risk assessment. Importantly, the awareness of PAD is low, and most PAD patients do not have typical leg symptoms of intermittent claudication.[17](#jah34369-bib-0017){ref-type="ref"} Also, diagnostic processes and signs/symptoms are unique for PAD (eg, leg examination, ABI measurement, and reduced leg pulse). Thus, identifying people at high lifetime risk of PAD may have implications on targeted patients' education about manifestation and complications of PAD. The risk calculator for prevalent PAD may have implications for screening PAD. Although it is still under debate,[19](#jah34369-bib-0019){ref-type="ref"}, [36](#jah34369-bib-0036){ref-type="ref"} some guidelines recommend screening PAD using ABI among high‐risk individuals.[19](#jah34369-bib-0019){ref-type="ref"} Although those clinical guidelines empirically rely on age and the presence of a few key risk factors to identify "high‐risk" populations for PAD (eg, all adults aged ≥65 years or people aged 50 to 64 years with any atherosclerotic risk factors[19](#jah34369-bib-0019){ref-type="ref"}), our risk calculator for prevalent PAD will allow healthcare providers and patients to quantify the risk objectively on the basis of a combination of risk factors.

Although we tried to use the best readily available data in the United States, we need to acknowledge several limitations. First, most data were collected in the 1990s or early 2000s, and, unfortunately, few contemporary US community‐based cohorts measured ABI in multiple racial/ethnic groups. Since a recent international study reported that the prevalence of PAD increased by 13% in high‐income countries from 2000 to 2010,[32](#jah34369-bib-0032){ref-type="ref"} our estimates may be conservative. On the other hand, the increase in prevalent PAD may be attributable to improved survival in people with PAD rather than an increased incidence, and thus a follow‐up investigation with contemporary data would be important. Also, we cannot deny the possibility of birth cohort effects on prevalence of PAD. Second, we could not reliably estimate lifetime risk of PAD over the age of 80 years because of sparse data in this age range in our data sets (eg, NHANES coded all ages older than 80 as age 80). Given extending life expectancy in the United States, this is another element indicating that our estimates are likely to be conservative. Third, as anticipated from the literature,[37](#jah34369-bib-0037){ref-type="ref"} the mortality rate in our cohorts tended to be lower than the mortality rate from vital statistics (Table [S5](#jah34369-sup-0001){ref-type="supplementary-material"}). However, our lifetime risk estimation is based on the mortality rate from vital statistics and relative risk from 6 US cohorts. Of note, cardiovascular relative risk of many risk factors including ABI has been shown to be often consistent regardless of the baseline risk of study populations.[8](#jah34369-bib-0008){ref-type="ref"}, [38](#jah34369-bib-0038){ref-type="ref"} Fourth, we did not have systematic data regarding history of leg revascularization across cohorts, indicating some level of underestimation by not capturing some PAD cases with ABI \>0.90 after vascular procedures. Fifth, a few cohorts did not have granular data of smoking status. Sixth, as true for almost any diagnostic tests, ABI is validated to diagnose PAD but is not perfect (sensitivity and specificity \>90%--95% in various studies[39](#jah34369-bib-0039){ref-type="ref"}, [40](#jah34369-bib-0040){ref-type="ref"}, [41](#jah34369-bib-0041){ref-type="ref"}, [42](#jah34369-bib-0042){ref-type="ref"}). For example, a high ABI may mask PAD in some individuals.[43](#jah34369-bib-0043){ref-type="ref"} Finally, although our data consisted of the 3 major racial/ethnic groups in the United States, data for other racial/ethnic groups were lacking.

In conclusion, ≈30% of blacks are estimated to develop PAD during their lifetime, whereas the estimate is ≈20% for whites and Hispanics. Unlike other atherosclerotic diseases, lifetime risk and the prevalence of PAD based on ABI \<0.90 was similar in women and in men. Among traditional atherosclerotic risk factors, age, smoking, and diabetes mellitus as well as a history of coronary disease or stroke are confirmed to be potent predictors of PAD risk and contributed to substantial variation of lifetime risk of PAD within the same race/ethnicity.
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